Skip to main content

Drug Interactions between Caprelsa and dabigatran

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dabigatran vandetanib

Applies to: dabigatran and Caprelsa (vandetanib)

MONITOR: Coadministration with vandetanib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein transporter, such as digoxin and dabigatran. The mechanism involves increased absorption and/or decreased clearance due to inhibition of drug efflux mediated by intestinal and renal/hepatic P-glycoprotein, respectively. Vandetanib is a weak P-glycoprotein inhibitor. The clinical significance is unknown. In healthy subjects, coadministration of a single 0.25 mg dose of digoxin with a 300 mg dose of vandetanib increased the mean digoxin Cmax by 29% and the mean AUC by 23%.

MANAGEMENT: Caution is advised if vandetanib must be used concomitantly with medications that are substrates of P-glycoprotein, particularly those with a narrow therapeutic range such as digoxin. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vandetanib is added to or withdrawn from therapy.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
  3. Cerner Multum, Inc. "Australian Product Information."
  4. (2011) "Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals
View all 4 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer